Loading...
AI-Driven Vaccine Partnerships And Dark Genome Targets Will Shape Long-Term Opportunity
AN
AnalystConsensusTarget
Not Invested
Based on Analyst Price Targets
Published
15 Dec 25
Views
13
15 Dec
US$3.79
AnalystConsensusTarget's Fair Value
US$14.19
73.3% undervalued intrinsic discount1Y
31.1%7D
7.1%1Y
31.1%7D
7.1%You can edit this narrative until Dec 16 11:05 AM. Then, changes will post as Updates.
Author's Valuation
US$14.1973.3% undervalued intrinsic discount
AnalystConsensusTarget Fair Value